Aragon finds investor with 'deep pockets' in $42m round for cancer combo development
This article was originally published in Scrip
Executive Summary
With the help of a new investor and $42 million in fresh capital, San Diego-based Aragon Pharmaceuticals can continue Phase II studies for its castration-resistant prostate cancer drug ARN-509 without a pharmaceutical partner and advance its preclinical breast cancer compound.